Y-mAbs Therapeutics, Inc. - Common Stock (YMAB)
4.7000
-0.1000 (-2.08%)
NASDAQ · Last Trade: Jun 27th, 5:10 PM EDT
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · June 27, 2025
Via Benzinga · June 27, 2025
Via Benzinga · May 19, 2025

Via Benzinga · March 5, 2025

Via Benzinga · November 18, 2024

Via Benzinga · November 7, 2024
Via Benzinga · April 28, 2025
Via Benzinga · April 22, 2025
Via Benzinga · March 21, 2025
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · March 13, 2025

Via Benzinga · August 13, 2024
Via Benzinga · March 13, 2025

Via Benzinga · January 7, 2025

Via Benzinga · November 22, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via Benzinga · October 30, 2024

The company didn't quite meet expectations for either trailing results or full-year guidance.
Via The Motley Fool · August 12, 2024

YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 12, 2024

Via Benzinga · August 12, 2024

Via Benzinga · July 2, 2024

YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024